Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
R

ESMO 2023 Insights: "AIM-HN Study - Evaluating Tipifarnib in mHRAS, Recurrent or Metastatic HNSCC"

By Dana-Farber Cancer Institute FEATURING Robert Haddad
By Dana-Farber Cancer Institute FEATURING Robert Haddad
77 views
November 6, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse
Head and Neck
02:34

ESMO 2023 Insights: "AIM-HN Study - Evaluating Tipifarnib in mHRAS, …

Dana-Farber Cancer Institute

R. Haddad

77 views